Compositions and methods for managing disorders

Abstract

Disclosed herein are methods for managing disorders or conditions, or treating symptoms of disorders or conditions, comprising administering 5HT receptor agonists. Also disclosed herein are pharmaceutical compositions, formulations. and dosage forms of 5HT receptor agonists.

What is claimed is: 
     
         1 . A method of improving motivation or cognitive engagement in a subject in need thereof the method comprising administering to the subject a pharmaceutical composition comprising:
 a) a therapeutically effective and non-hallucinogenic amount of psilocybin or psilocin, wherein the psilocybin or psilocin is in an amount of about 0.1 mg to about 6 mg, and   b) a pharmaceutically acceptable excipient, 
 wherein the therapeutically effective and non-hallucinogenic amount of the psilocybin or psilocin is provided to the subject in need thereof in an amount insufficient to provide a hallucinogenic experience. 
   
     
     
         2 . The method of  claim 1 , wherein the subject is suffering from a mood or cognitive disorder. 
     
     
         3 . The method of  claim 1 , wherein the subject is suffering from an anxiety, cognitive, or depression disorder. 
     
     
         4 . The method of  claim 3 , wherein the subject is suffering from an anxiety disorder. 
     
     
         5 . The method of  claim 4 , wherein anxiety’ disorder is generalized anxiety disorder. 
     
     
         6 . The method of  claim 3 , wherein the subject is suffering from cognitive disorder, and the cognitive disorder is an attention disorder. 
     
     
         7 . The method of  claim 3 , wherein the method is for treating the anxiety, cognitive, or depression disorder. 
     
     
         8 . The method of  claim 1 , wherein the therapeutically effective and non-hallucinogenic amount of the psilocybin or psilocin is no more than 5 mg. 
     
     
         9 . The method of  claim 1 , wherein the therapeutically effective and non-hallucinogenic amount of the psilocybin or psilocin is about 0.5 mg to about 4 mg. 
     
     
         10 . The method of  claim 1 , wherein the therapeutically effective and non-hallucinogenic amount of the psilocybin or psilocin is no more than 3.5 mg. 
     
     
         11 . The method of  claim 1 , wherein the therapeutically effective and non-hallucinogenic amount of the psilocybin or psilocin is about 0.5 mg to about 2.5 mg. 
     
     
         12 . The method of  claim 1 , wherein the therapeutically effective and non-hallucinogenic amount of the psilocybin or psilocin is provided to the subject in need thereof in an amount and/or formulation to provide a maximum plasma concentration (C max ) of active form of the psilocybin or psilocin of about 0.5 ng/mL or more and less than 6 ng/mL. 
     
     
         13 . The method of  claim 1 , wherein the therapeutically effective and non-hallucinogenic amount of the psilocybin or psilocin is provided to the subject in need thereof in an amount and/or formulation to provide a maximum plasma concentration (C max ) of active form of the psilocybin or psilocin of no more than 4.5 ng/mL. 
     
     
         14 . The method of  claim 1 , wherein the therapeutically effective and non-hallucinogenic amount of the psilocybin or psilocin is provided to the subject in need thereof in an amount and/or formulation to provide a maximum plasma concentration (C max ) of active form of the psilocybin or psilocin of about 0.5 ng/mL to about 4.5 ng/mL. 
     
     
         15 . The method of  claim 1 , wherein the therapeutically effective and non-hallucinogenic amount of the psilocybin or psilocin is provided to the subject in need thereof in an amount and/or formulation to provide a maximum plasma concentration (C max ) of active form of the psilocybin or psilocin of about 2 ng/mL to about 4.5 ng/mL. 
     
     
         16 . The method of  claim 1 , wherein the therapeutically effective and non-hallucinogenic amount of the psilocybin or psilocin is provided to the subject in need thereof in an amount and/or formulation to provide a maximum plasma concentration (C max ) of active form of the psilocybin or psilocin of about 0.5 ng/mL to about 3 ng/mL. 
     
     
         17 . The method of  claim 1 , wherein the therapeutically effective and non-hallucinogenic amount of the psilocybin or psilocin is provided to the subject in need thereof in an amount and/or formulation to provide a plasma concentration of active form of the psilocybin or psilocin of at least 0.1 ng/mL after at least 6 hours. 
     
     
         18 . The method of  claim 1 , wherein the therapeutically effective and non-hallucinogenic amount of the psilocybin or psilocin is provided to the subject in need thereof in an amount and/or formulation to provide a plasma concentration of active form of the psilocybin or psilocin of at least 0.5 ng/mL after at least 6 hours. 
     
     
         19 . The method of  claim 1 , wherein the pharmaceutical composition is administered orally. 
     
     
         20 . The method of  claim 1 , wherein the psilocybin or psilocin is provided in an amount insufficient to provide a perturbation in the subject’s sense of reality or perceptions.